sovaprevir + peginterferon alfa-2a + ribavirin

A combination regimen consisting of **sovaprevir** (an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor), **peginterferon alfa-2a** (a pegylated recombinant form of interferon alfa-2a), and **ribavirin** (a synthetic nucleoside analogue). - Sovaprevir inhibits the HCV NS3/4A protease, blocking viral polyprotein cleavage and replication. - Peginterferon alfa-2a modulates immune response by inducing antiviral proteins, enhancing cellular immunity, and suppressing HCV replication. - Ribavirin inhibits viral RNA synthesis and promotes lethal mutagenesis of the virus. This triple therapy was developed for the treatment of chronic HCV infection, particularly before the widespread adoption of direct-acting antivirals. Sovaprevir was specifically developed as part of regimens combining these agents, but this combination has largely been superseded by newer therapies with improved efficacy and safety. The main indication targeted for this combination was chronic hepatitis C infection in adults, including those with difficult-to-treat genotypes.